Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
VIEKIRA PAK is a fixed-dose combination of three direct-acting antivirals (dasabuvir, ombitasvir, paritaprevir) plus ritonavir, administered orally as tablets. It treats chronic hepatitis C virus (HCV) infection by simultaneously inhibiting NS5A, NS5B, and NS3/4A viral proteases to suppress viral replication. The copackaged formulation simplifies treatment regimens and improves patient adherence.
Peak-stage product with mature commercial infrastructure; commercial teams are focused on maximizing market penetration and managing specialty pharmacy relationships in a competitive HCV market.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on VIEKIRA PAK provides solid experience in specialty pharmaceutical marketing and managed care navigation within a mature, competitive therapeutic area. Professionals should expect focus on payer negotiations, prior authorization optimization, and managed decline planning as the product approaches loss of exclusivity.
Worked on VIEKIRA PAK (COPACKAGED) at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo